Nasdaq · CIK 0001620463
LONA Athira Pharma, Inc.
Insider trading from SEC Form 4. Last filing Jul 2, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Athira Pharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Robert Renninger SVP, Finance and Accounting sell | $850 2,897 shares | -3% | - | |
| 15Weak | Mark Worthington General Counsel and CCO sell | $2,502 8,526 shares | -7% | - | |
| 20Weak | Martin Javier San CHIEF MEDICAL OFFICER sell | $3,182 10,842 shares | -13% | - | |
| 25Weak | Mark James Litton President and CEO sell | $7,374 25,123 shares | -7% | - | |
| 15Weak | Church Kevin CHIEF SCIENTIFIC OFFICER sell | $2,502 8,526 shares | -5% | - | |
| 15Weak | Mark Worthington General Counsel and CCO sell | $4,782 8,510 shares | -9% | - | |
| 15Weak | Robert Renninger VP of Finance sell | $1,619 2,881 shares | -3% | - | |
| 15Weak | Church Kevin CHIEF SCIENTIFIC OFFICER sell | $4,782 8,510 shares | -6% | - | |
| 25Weak | Mark James Litton President and CEO sell | $14k 25,107 shares | -9% | - | |
| 20Weak | Martin Javier San CHIEF MEDICAL OFFICER sell | $6,083 10,826 shares | -23% | - |
Transactions
The last 53 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | Mark Worthington General Counsel and CCO | MOption exercise Common Stock | +36,666 | $0.00 | $0 | 120,401 | Jul 2, 2025 |
| Jun 30, 2025 | Martin Javier San CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +46,666 | $0.00 | $0 | 82,507 | Jul 2, 2025 |
| Jun 30, 2025 | Mark James Litton President and CEO | MOption exercise Common Stock | +108,334 | $0.00 | $0 | 350,925 | Jul 2, 2025 |
| May 19, 2025 | Church Kevin CHIEF SCIENTIFIC OFFICER | AGrant or award Common Stock | +10,000 | $0.23 | $2,312 | 140,761 | Jul 2, 2025 |
| May 19, 2025 | Robert Renninger SVP, Finance and Accounting | AGrant or award Common Stock | +10,000 | $0.23 | $2,312 | 99,724 | Jul 2, 2025 |
| Jul 1, 2025 | Mark Worthington General Counsel and CCO | SOpen-market sale Common Stock | -8,526 | $0.29 | $2,502 | 111,875 | Jul 2, 2025 |
| Jul 1, 2025 | Martin Javier San CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -10,842 | $0.29 | $3,182 | 71,665 | Jul 2, 2025 |
| Jul 1, 2025 | Mark James Litton President and CEO | SOpen-market sale Common Stock | -25,123 | $0.29 | $7,374 | 325,802 | Jul 2, 2025 |
| Jun 30, 2025 | Robert Renninger SVP, Finance and Accounting | MOption exercise Common Stock | +12,359 | $0.00 | $0 | 112,083 | Jul 2, 2025 |
| Jun 30, 2025 | Church Kevin CHIEF SCIENTIFIC OFFICER | MOption exercise Common Stock | +36,666 | $0.00 | $0 | 177,427 | Jul 2, 2025 |
| Jul 1, 2025 | Church Kevin CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock | -8,526 | $0.29 | $2,502 | 168,901 | Jul 2, 2025 |
| Jul 1, 2025 | Robert Renninger SVP, Finance and Accounting | SOpen-market sale Common Stock | -2,897 | $0.29 | $850 | 109,186 | Jul 2, 2025 |
| Jun 30, 2025 | Mark Worthington General Counsel and CCO | MOption exercise Restricted Stock Unitsderivative | -36,666 | $0.00 | $0 | 36,667 | Jul 2, 2025 |
| Jun 30, 2025 | Martin Javier San CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -46,666 | $0.00 | $0 | 46,667 | Jul 2, 2025 |
| Jun 30, 2025 | Church Kevin CHIEF SCIENTIFIC OFFICER | MOption exercise Restricted Stock Unitsderivative | -36,666 | $0.00 | $0 | 36,667 | Jul 2, 2025 |
| Jun 30, 2025 | Robert Renninger SVP, Finance and Accounting | MOption exercise Restricted Stock Unitsderivative | -12,359 | $0.00 | $0 | 12,359 | Jul 2, 2025 |
| Jun 30, 2025 | Mark James Litton President and CEO | MOption exercise Restricted Stock Unitsderivative | -108,334 | $0.00 | $0 | 108,333 | Jul 2, 2025 |
| May 30, 2025 | Grant Pickering director | AGrant or award Stock Option (Right to Buy)derivative | +20,900 | $0.00 | $0 | 20,900 | Jun 3, 2025 |
| May 30, 2025 | Barbara Kosacz director | AGrant or award Stock Option (Right to Buy)derivative | +20,900 | $0.00 | $0 | 20,900 | Jun 3, 2025 |
| May 30, 2025 | James A Johnson director | AGrant or award Stock Option (Right to Buy)derivative | +20,900 | $0.00 | $0 | 20,900 | Jun 3, 2025 |
| May 30, 2025 | Joseph Edelman director | AGrant or award Stock Option (Right to Buy)derivative | +20,900 | $0.00 | $0 | 20,900 | Jun 3, 2025 |
| May 30, 2025 | Kelly A Romano director | AGrant or award Stock Option (Right to Buy)derivative | +20,900 | $0.00 | $0 | 20,900 | Jun 3, 2025 |
| May 30, 2025 | Michael A. Panzara director | AGrant or award Stock Option (Right to Buy)derivative | +20,900 | $0.00 | $0 | 20,900 | Jun 3, 2025 |
| May 30, 2025 | John M Fluke Jr director | AGrant or award Stock Option (Right to Buy)derivative | +20,900 | $0.00 | $0 | 20,900 | Jun 3, 2025 |
| Mar 3, 2025 | Martin Javier San CHIEF MEDICAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +111,270 | $0.00 | $0 | 111,270 | Mar 4, 2025 |
| Mar 3, 2025 | Robert Renninger SVP, Finance and Accounting | AGrant or award Stock Option (Right to Buy)derivative | +58,500 | $0.00 | $0 | 58,500 | Mar 4, 2025 |
| Mar 3, 2025 | Church Kevin CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +87,845 | $0.00 | $0 | 87,845 | Mar 4, 2025 |
| Mar 3, 2025 | Mark James Litton President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +333,815 | $0.00 | $0 | 333,815 | Mar 4, 2025 |
| Mar 3, 2025 | Mark Worthington General Counsel and CCO | AGrant or award Stock Option (Right to Buy)derivative | +85,895 | $0.00 | $0 | 85,895 | Mar 4, 2025 |
| Mar 3, 2025 | Mark James Litton President and CEO | AGrant or award Restricted Stock Unitsderivative | +222,543 | $0.00 | $0 | 222,543 | Mar 4, 2025 |
| Mar 3, 2025 | Mark Worthington General Counsel and CCO | AGrant or award Restricted Stock Unitsderivative | +57,263 | $0.00 | $0 | 57,263 | Mar 4, 2025 |
| Mar 3, 2025 | Church Kevin CHIEF SCIENTIFIC OFFICER | AGrant or award Restricted Stock Unitsderivative | +58,563 | $0.00 | $0 | 58,563 | Mar 4, 2025 |
| Mar 3, 2025 | Robert Renninger SVP, Finance and Accounting | AGrant or award Stock Option (Right to Buy)derivative | +73,350 | $0.00 | $0 | 73,350 | Mar 4, 2025 |
| Mar 3, 2025 | Martin Javier San CHIEF MEDICAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +74,180 | $0.00 | $0 | 74,180 | Mar 4, 2025 |
| Mar 3, 2025 | Robert Renninger SVP, Finance and Accounting | AGrant or award Restricted Stock Unitsderivative | +39,000 | $0.00 | $0 | 39,000 | Mar 4, 2025 |
| Nov 18, 2024 | Church Kevin CHIEF SCIENTIFIC OFFICER | AGrant or award Common Stock | +9,920 | $0.55 | $5,456 | 102,604 | Jan 3, 2025 |
| Nov 18, 2024 | Robert Renninger VP of Finance | AGrant or award Common Stock | +3,651 | $0.55 | $2,008 | 80,246 | Jan 3, 2025 |
| Nov 18, 2024 | Mark Worthington General Counsel and CCO | AGrant or award Common Stock | +3,651 | $0.55 | $2,008 | 55,578 | Jan 3, 2025 |
| Dec 31, 2024 | Martin Javier San CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +46,667 | $0.00 | $0 | 46,667 | Jan 3, 2025 |
| Dec 31, 2024 | Mark James Litton President and CEO | MOption exercise Common Stock | +108,333 | $0.00 | $0 | 267,698 | Jan 3, 2025 |
| Dec 31, 2024 | Mark Worthington General Counsel and CCO | MOption exercise Common Stock | +36,667 | $0.00 | $0 | 92,245 | Jan 3, 2025 |
| Dec 31, 2024 | Robert Renninger VP of Finance | MOption exercise Common Stock | +12,359 | $0.00 | $0 | 92,605 | Jan 3, 2025 |
| Dec 31, 2024 | Church Kevin CHIEF SCIENTIFIC OFFICER | MOption exercise Common Stock | +36,667 | $0.00 | $0 | 139,271 | Jan 3, 2025 |
| Jan 2, 2025 | Martin Javier San CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -10,826 | $0.56 | $6,083 | 35,841 | Jan 3, 2025 |
| Jan 2, 2025 | Mark James Litton President and CEO | SOpen-market sale Common Stock | -25,107 | $0.56 | $14k | 242,591 | Jan 3, 2025 |
| Dec 31, 2024 | Martin Javier San CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -46,667 | $0.00 | $0 | 93,333 | Jan 3, 2025 |
| Jan 2, 2025 | Church Kevin CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock | -8,510 | $0.56 | $4,782 | 130,761 | Jan 3, 2025 |
| Jan 2, 2025 | Robert Renninger VP of Finance | SOpen-market sale Common Stock | -2,881 | $0.56 | $1,619 | 89,724 | Jan 3, 2025 |
| Jan 2, 2025 | Mark Worthington General Counsel and CCO | SOpen-market sale Common Stock | -8,510 | $0.56 | $4,782 | 83,735 | Jan 3, 2025 |
| Dec 31, 2024 | Mark Worthington General Counsel and CCO | MOption exercise Restricted Stock Unitsderivative | -36,667 | $0.00 | $0 | 73,333 | Jan 3, 2025 |
| Dec 31, 2024 | Robert Renninger VP of Finance | MOption exercise Restricted Stock Unitsderivative | -12,359 | $0.00 | $0 | 24,718 | Jan 3, 2025 |
| Dec 31, 2024 | Church Kevin CHIEF SCIENTIFIC OFFICER | MOption exercise Restricted Stock Unitsderivative | -36,667 | $0.00 | $0 | 73,333 | Jan 3, 2025 |
| Dec 31, 2024 | Mark James Litton President and CEO | MOption exercise Restricted Stock Unitsderivative | -108,333 | $0.00 | $0 | 216,667 | Jan 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Church KevinCHIEF SCIENTIFIC OFFICER
- Joseph Edelmandirector, owner
- John M Fluke Jrdirector
- James A Johnsondirector
- Barbara Kosaczdirector
- Mark James LittonPresident and CEO
- Grant Pickeringceo, officer, director
- Michael A. Panzaradirector
- Robert RenningerSVP, Finance and Accounting
- Kelly A Romanodirector
- Martin Javier SanCHIEF MEDICAL OFFICER
- Mark WorthingtonGeneral Counsel and CCO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.